Management of Spontaneously Resolved Supraventricular Tachycardia (SVT)
Acute Assessment and Ongoing Management
- The American College of Cardiology recommends obtaining a 12-lead ECG to look for pre-excitation patterns or other abnormalities that might indicate the SVT mechanism, with a Class I recommendation for ongoing management 1, 3
- The American Heart Association suggests teaching patients how to perform vagal maneuvers for future episodes, as this is a Class I recommendation for ongoing management 1, 4
Pharmacological Management
- The American College of Cardiology recommends oral beta blockers, diltiazem, or verapamil as first-line therapy for symptomatic patients without ventricular pre-excitation during sinus rhythm, with a Class I recommendation 1, 4
- The American Heart Association suggests flecainide or propafenone as second-line medications for patients without structural heart disease who cannot undergo or prefer not to have catheter ablation, with a Class IIa recommendation 1, 4
Definitive Treatment
- The American College of Cardiology recommends electrophysiological study with the option of catheter ablation as the definitive diagnostic and therapeutic approach, with a Class I recommendation and success rates of 94-98% 1
Management Algorithm
- For patients with infrequent episodes (1-2 per year), the American Heart Association recommends teaching vagal maneuvers for acute termination of future episodes, with a Class I recommendation 1, 4
- For patients with frequent episodes (>2 per year), the American College of Cardiology recommends starting with oral beta blockers, diltiazem, or verapamil for symptom control, with a Class I recommendation 1, 4
Special Considerations
- The American Heart Association cautions against using calcium channel blockers and beta blockers in patients with severe conduction abnormalities or sinus node dysfunction 6
- The American College of Cardiology recommends against synchronized cardioversion for SVTs that terminate and reinitiate spontaneously 1, 3